Skip to content

US · TWST · MEDICAL - DIAGNOSTICS & RESEARCH

Twist Bioscience Corporation (TWST) intrinsic value and stock valuation

$103.32as of 2026-11-21 · Mkt cap 7.16B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Twist Bioscience Corporation DCF and intrinsic value

InvestorsCraft values TWST with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from TWST’s statements →

Twist Bioscience Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research South San Francisco, CA 94080 twistbioscience.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$376.6M+33.1% 5y CAGRd
20162025
Net income
-$-77.67M
20162025
Free cash flow
-$-75.63M
20162025
Total equity
$473M+7.1% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$376.6M$313M$245.1M$203.6M$132.3M
Operating income-$-136.26M-$-220.83M-$-217.16M-$-234.78M-$-152.73M
Net income-$-77.67M-$-208.73M-$-204.62M-$-217.86M-$-152.1M
EPSd-$-1.3M-$-3.6M-$-3.6M-$-4.04M-$-3.15M
Operating cash flow-$-47.63M-$-64.09M-$-142.47M-$-124.39M-$-112.24M
Capital expenditure-$-28M-$-5.08M-$-27.78M-$-101.86M-$-27.06M
Free cash flow-$-75.63M-$-69.17M-$-170.25M-$-226.24M-$-139.31M
Total assets$641.9M$614.3M$776.4M$961.4M$702.1M
Total debt$137.3M$85M$94.1M$94.9M$62.9M
Net debt-$-45.73M-$-141.29M-$-192.4M-$-283.77M-$-402.91M
Total equity$473M$472.7M$623.4M$789.4M$580.8M
Cash and short-term investments$232.4M$276.4M$336.4M$505M$477.9M
Income statement
20252024202320222021
Revenue$376.6M$313M$245.1M$203.6M$132.3M
Cost of revenue$185.6M$179.6M$155.4M$119.3M$80.6M
Gross profit$191M$133.4M$89.7M$84.2M$51.7M
Research and development expenses$80.3M$90.9M$106.9M$120.3M$69.1M
Selling, general and administrative expenses$247M$218.4M$189.7M$213M$135.9M
Other expenses$0.00$44.9M$10.3M-$-14.24M-$-530K
Operating expenses$327.3M$354.2M$306.9M$319M$204.4M
Cost and expenses$512.8M$533.8M$462.3M$438.3M$285.1M
Interest income$11.4M$15.3M$14.4M$3.06M$430K
Interest expense$0.00$30K$10K$80K$370K
Depreciation and amortization$24.9M$31.4M$29.3M$16.5M$9.75M
Ebitda-$-52.1M-$-176.71M-$-174.15M-$-211.68M-$-143.91M
Operating income-$-136.26M-$-220.83M-$-217.16M-$-234.78M-$-152.73M
Total other income/expenses, net$59.3M$12.7M$13.7M$6.5M-$-1.3M
Income before tax-$-76.95M-$-208.17M-$-203.47M-$-228.27M-$-154.03M
Income tax expense$720K$560K$1.15M-$-10.41M-$-1.93M
Net income-$-77.67M-$-208.73M-$-204.62M-$-217.86M-$-152.1M
Weighted average shares outstanding$59.8M$58M$56.9M$53.9M$48.3M
Weighted average diluted shares outstanding$59.8M$58M$56.9M$53.9M$48.3M
Balance sheet
20252024202320222021
Cash and short-term investments$232.4M$276.4M$336.4M$505M$477.9M
Net receivables$57.3M$34.9M$44.1M$40.3M$28.6M
Inventory$28.3M$24.1M$32.1M$39.3M$31.8M
Total current assets$333M$346.8M$424.3M$596.5M$546.5M
Property, plant and equipment, net$151.7M$161.4M$203.4M$214.4M$105.7M
Goodwill and intangible assets$95.6M$100.3M$140.3M$145.6M$40.7M
Long-term investments$54.3M$1.52M$2.81M$0.00$0.00
Total non-current assets$308.9M$267.6M$352.2M$364.9M$155.6M
Total assets$641.9M$614.3M$776.4M$961.4M$702.1M
Accounts payable$11.1M$1.63M$14.1M$20.1M$14.9M
Short-term debt$13.8M$14.8M$14.9M$13.6M$9.77M
Deferred revenue$6.88M$2.13M$3M$3.48M$1.09M
Total current liabilities$91.4M$71M$73.3M$90.7M$63.1M
Long-term debt$123.5M$70.2M$79.2M$81.3M$53.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$77.5M$70.6M$79.7M$81.3M$58.2M
Capital lease obligations$61.8M$85M$94.1M$94.9M$61.4M
Total liabilities$168.9M$141.6M$153M$172M$121.3M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-1.32B-$-1.24B-$-1.03B-$-828.42M-$-610.55M
Accumulated other comprehensive income (loss)-$-630K-$-520K-$-760K-$-1.84M$550K
Total equity$473M$472.7M$623.4M$789.4M$580.8M
Total investments$103.7M$51.6M$52.8M$126.3M$12M
Total debt$137.3M$85M$94.1M$94.9M$62.9M
Net debt-$-45.73M-$-141.29M-$-192.4M-$-283.77M-$-402.91M
Cash flow statement
20252024202320222021
Net income-$-77.67M-$-208.73M-$-204.62M-$-217.86M-$-152.1M
Depreciation and amortization$24.9M$31.4M$29.3M$16.5M$9.75M
Stock-based compensation$64.5M$50.9M$30.3M$79.7M$37M
Change in working capital-$-12.61M$15.4M-$-1.01M-$-5.36M-$-9.38M
Accounts receivable-$-22.38M$8.44M-$-4.32M-$-9.62M-$-2.2M
Inventory-$-4.23M$7.99M$7.24M-$-7.54M-$-19.49M
Accounts payable$9.33M-$-11.8M-$-2.51M$7.38M$8.54M
Net cash provided by operating activities-$-47.63M-$-64.09M-$-142.47M-$-124.39M-$-112.24M
Investments in property, plant and equipment-$-28M-$-5.08M-$-27.78M-$-101.86M-$-27.06M
Acquisitions, net$2.5M$0.00$5.86M-$-8.16M-$-480K
Net cash used for investing activities-$-24.76M-$-3.07M$50.6M-$-232.93M$156.2M
Common stock issued$13.6M$0.00$0.00$269.8M$323.9M
Common stock repurchased-$-20K-$-3.98M-$-4.41M-$-7.75M-$-10.85M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$28.5M$6.89M$910K$270.5M$329.2M
Net change in cash-$-43.27M-$-60.15M-$-90.98M-$-87.1M$373.1M
Cash at end of period$183.1M$229.1M$289.3M$380.3M$467.4M
Operating cash flow-$-47.63M-$-64.09M-$-142.47M-$-124.39M-$-112.24M
Capital expenditure-$-28M-$-5.08M-$-27.78M-$-101.86M-$-27.06M
Free cash flow-$-75.63M-$-69.17M-$-170.25M-$-226.24M-$-139.31M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Twist Bioscience Corporation

        Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

        CEO
        Emily Marine Leproust
        Employees
        979
        Beta
        2.12

        Explore

        Frequently asked questions

        What is the intrinsic value of Twist Bioscience Corporation (TWST)?

        Twist Bioscience Corporation (TWST) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TWST undervalued?

        TWST trades at a price of $103.32 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.